A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer†

M. Ueno1*, T. Okusaka2, Y. Omuoro3, H. Isayama4, A. Fukutomi5, M. Ikeda6, N. Mizuno7, K. Fukuzawa8, M. Furukawa9, H. Iguchi10, K. Sugimori11, J. Furuse12, K. Shimada13, T. Ioka14, S. Nakamori15, H. Baba16, Y. Komatsu17, M. Takeuchi18, I. Hyodo19 & N. Boku20

1Division of Hepatobiliary and Pancreatic Medical Oncology, Kanagawa Cancer Center, Yokohama; 2Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo; 3Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo; 4Department of Gastroenterology, The University of Tokyo, Graduate School of Medicine, Tokyo; 5Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka; 6Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa; 7Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya; 8Department of Surgery, Oita Red Cross Hospital, Oita; 9Department of Gastroenterology, National Kyushu Cancer Center, Fukuoka; 10Department of Gastroenterology, National Hospital Organization Shikoku Cancer Center, Matsuyama; 11Gastroenterological Center, Yokohama City University Medical Center, Yokohama; 12Department of Medical Oncology, Kyorin University School of Medicine, Tokyo; 13Department of Medical Oncology, Saitama Medical University International Medical Center, Saitama; 14Department of Hepatobiliary and Pancreatic Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka; 15Hepato-biliary-pancreatic Surgery, National Hospital Organization Osaka National Hospital, Osaka; 16Department of Gastroenterological Surgery, Kumamoto University, Kumamoto; 17Department of Cancer Chemotherapy, Hokkaido University Hospital Cancer Center, Sapporo; 18Department of Clinical Medicine (Biostatistics and Pharmaceutical Medicine), Kitasato University School of Pharmacy, Tokyo; 19Division of Gastroenterology, University of Tsukuba, Tsukuba; 20Department of Clinical Oncology, St Marianna University School of Medicine, Kawasaki, Japan

Received 13 July 2015; revised 4 November 2015; accepted 1 December 2015

Background: We evaluated the efficacy and toxicity of adding oral leucovorin (LV) to S-1 when compared with S-1 monotherapy in patients with gemcitabine-refractory pancreatic cancer (PC).

Patients and methods: Gemcitabine-refractory PC patients were randomly assigned in a 1:1 ratio to receive S-1 at 40, 50, or 60 mg according to body surface area plus LV 25 mg, both given orally twice daily for 1 week, repeated every 2 weeks (SL group), or S-1 monotherapy at the same dose as the SL group for 4 weeks, repeated every 6 weeks (S-1 group). The primary end point was progression-free survival (PFS).

Results: Among 142 patients enrolled, 140 were eligible for efficacy assessment (SL: n = 69 and S-1: n = 71). PFS was significantly longer in the SL group than in the S-1 group [median PFS, 3.8 versus 2.7 months; hazard ratio (HR), 0.56; 95% confidence interval (CI), 0.37–0.85; P = 0.003]. The disease control rate was significantly higher in the SL group than in the S-1 group (91% versus 72%; P = 0.004). Overall survival (OS) was similar in both groups (median OS, 6.3 versus 6.1 months; HR, 0.82; 95% CI, 0.54–1.22; P = 0.463). After adjusting for patient background factors in a multivariate analysis, OS tended to be better in the SL group (HR, 0.71; 95% CI, 0.47–1.07; P = 0.099). Both treatments were well tolerated, although gastrointestinal toxicities were slightly more severe in the SL group.

Conclusion: The addition of LV to S-1 significantly improved PFS in patients with gemcitabine-refractory advanced PC, and a phase III trial has been initiated in a similar setting.

Clinical trials number: Japan Pharmaceutical Information Center: JapicCTI-111554.

Key words: phase II study, S-1, leucovorin, gemcitabine-refractory pancreatic cancer, pancreatic resection, albumin

Introduction

Pancreatic cancer (PC), known for its poor prognosis, is the eighth leading cause of cancer-related mortality in the world [1]. Although FOLFIRINOX has become a standard regimen for advanced PC, its use is limited to patients in good medical condition because of its severe toxicity [2]. Gemcitabine plus nab-paclitaxel is another treatment option for patients in fair
condition [3]. Some patients still receive gemcitabine monotherapy as first-line treatment.

Even with intensive chemotherapy regimens such as FOLFIRINOX and gemcitabine plus nab-paclitaxel, the median progression-free survival (PFS) is ~6 months. Furthermore, a considerable number of patients cannot tolerate intensive chemotherapy after first-line chemotherapy. Although a combination of oxaliplatin, leucovorin (LV), and fluorouracil (OFF) prolonged survival when compared with fluorouracil plus LV (FF) after gemcitabine failure (CONKO-003 trial) [4], there are various unmet needs that should be addressed in a second-line setting for advanced PC.

In Japan, S-1 (Taiho Pharmaceutical Co., Ltd, Tokyo, Japan), an oral fluoropyrimidine that inhibits dihydropyrimidine dehydrogenase, has been demonstrated to be non-inferior to gemcitabine as first-line chemotherapy for advanced PC [5]. In gemcitabine-refractory patients, a previous phase II study reported that S-1 was moderately effective, with a response rate (RR) of 15%, a median PFS of 2.0 months, and a median overall survival (OS) of 4.5 months [6]. Furthermore, although oxaliplatin and irinotecan can be key drugs, neither S-1 plus oxaliplatin nor S-1 plus irinotecan provided a survival benefit over S-1 monotherapy in patients with gemcitabine-refractory PC [7, 8]. Because S-1 monotherapy is less toxic than these doublet regimens, it is widely used in gemcitabine-refractory patients as the practical standard care in Japan. LV is known to enhance the efficacy of fluorouracil in metastatic colorectal cancer (CRC) [9]. In preclinical studies, combined treatment with LV and S-1 was suggested to enhance therapeutic efficacy [10]. A randomized phase II study suggested that adding to LV to capcitabine might not increase efficacy because of increased intolerable toxicities [11]. Given the time-dependent antitumor effects and toxicities of fluoropyrimidine plus LV, various schedules of S-1 plus LV (SL) were studied in metastatic CRC, and a 2-week schedule (1 week on, 1 week off) was designated as the optimal schedule, maintaining high antitumor efficacy with manageable toxicity [12, 13]. These findings encouraged us to perform a randomized phase II clinical trial comparing SL with S-1 monotherapy in patients with gemcitabine-refractory advanced PC.

methods

study design

This multicenter, open-labeled, randomized phase II study, sponsored by Taiho Pharmaceutical Co., Ltd, Tokyo, Japan, was conducted at 27 centers in compliance with the Declaration of Helsinki and Good Clinical Practice guidelines. An independent data and safety monitoring committee reviewed efficacy and safety data. The study protocol was approved by the institutional review board of each participating center. All patients provided written informed consent before study entry.

patients

Eligible patients were 20–79 years of age and had a histologically or cytologically confirmed diagnosis of adenocarcinoma or adenosquamous carcinoma of the pancreas that was refractory to first-line treatment with gemcitabine. Patients had measurable lesions according to the Response Evaluation Criteria in Solid Tumors (RECIST; version 1.1). Other eligibility criteria were as follows: (i) no prior radiotherapy for PC, (ii) an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1, and (iii) adequate bone-marrow, hepatic, and renal functions on laboratory tests carried out within 7 days before enrollment. Patients could have no serious comorbidities (supplementary Appendix SA2, available at Annals of Oncology online).

Disease progression during first-line gemcitabine-based chemotherapy or recurrence during or within 6 months after the completion of postoperative adjuvant gemcitabine chemotherapy was assessed on computed tomography (CT), magnetic resonance imaging (MRI), or other imaging techniques and was confirmed by an independent review committee (IRC).

randomization

After confirming eligibility, patients were randomly assigned in a 1:1 ratio to receive S-1 plus LV (SL group) or S-1 monotherapy (S-1 group). Random assignment was carried out centrally at an independent data center by the minimization method, using the duration of prior gemcitabine treatment (≤6 versus >6 months) and ECOG PS (0 versus 1) as allocation factors.

treatment

The dose of S-1 was determined according to the body surface area as follows: ≤1.25 m², 40 mg; 1.25 to ≤1.5 m², 50 mg; ≥1.5 m², 60 mg, given twice daily after meals in both treatment groups. In the SL group, LV at a fixed dose of 25 mg was additionally given with each dose of S-1. Patients assigned to the S-1 group received S-1 plus LV orally for 1 week, followed by a 1-week rest, repeated every 2 weeks. Patients assigned to the S-1 group received the same dose of S-1 orally for 4 consecutive weeks, followed by a 2-week rest, repeated every 6 weeks. The details of dose modification of S-1 are defined in supplementary Appendix SA3, available at Annals of Oncology online. Treatment was continued until disease progression, unacceptable toxic effects, or the withdrawal of consent.

assessments

Patients’ conditions were assessed every 2 weeks during the protocol treatment. All adverse events were evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0). CT or MRI was carried out every 4 weeks during the first 16 weeks and every 6 weeks thereafter until disease progression. Response was assessed by the attending physicians and confirmed by the IRC according to RECIST version 1.1. If there was any discordance between an investigator and the IRC, the date of disease progression as evaluated by the IRC was used to calculate PFS. Data on patients in whom treatment was discontinued before disease progression was confirmed by the IRC were censored on the last day of tumor assessment (no events).

dependents

The primary end point was PFS, defined as the time from randomization to disease progression or death from any cause. Secondary end points were OS, RR, disease control rate (DCR), duration of response, time to treatment failure (TTF), time to progression (TPP), dose intensity, and adverse events (supplementary Appendix SA4, available at Annals of Oncology online).

statistical analysis

The hazard ratio (HR) for PFS was expected to be 0.67, corresponding to a median PFS of 3.0 months in the SL group and 2.0 months in the S-1 group. These estimates were based on the results of a previous study [6]. To detect such an improvement in the HR with ≥80% power and a one-sided significance level of 0.10, a total of 110 events of progressive disease confirmed by the IRC in the full analysis set (FAS) were required. Given a 10% loss of events due to discordance in the PFS assessment between the IRC and the investigators and a 5% dropout rate from the FAS for various reasons, the sample size was set at 140 patients. Time-to-event variables, such as PFS, OS, TTF, and TTP, were analyzed with the Kaplan–Meier method, and the HR for these end points was calculated with a Cox proportional-hazards model. Primary
comparisons of PFS between the treatment groups were made with the stratified log-rank test adjusted for allocation factors. The secondary end points of OS, TTF, and TTP were analyzed with the use of log-rank tests. RR and DCR were compared with the use of Fisher’s exact test. Interaction tests between treatment effect and patient characteristics were done for PFS and OS.

The FAS was based on all eligible patients, and the safety analysis set was defined as the patients who received the study treatment at least once. Data analyses were carried out with the use of SAS, version 9.2. Subset analyses were pre-planned.

**results**

**patients**

Between August 2011 and August 2012, a total of 142 patients were enrolled. All randomized patients were confirmed to have gemcitabine-refractory PC by the IRC. A total of 140 patients were eligible and included in the FAS (supplementary Figure S1, available at Annals of Oncology online). Two patients in the SL group were ineligible because they had no target lesions on IRC assessment. There were some imbalances in patient characteristics, such as the serum albumin level, sum of the diameters of target lesions, and prior pancreatic resection (Table 1).

**efficacy**

At the cut-off date for PFS analysis of 17 December 2012, when 117 events had been reported by the investigators, 97 events were confirmed, and data on 25 patients were censored by the IRC. The median PFS was 3.8 months [95% confidence interval (CI), 3.7–6.0 months] in the SL group and 2.7 months (95% CI, 1.9–3.7 months) in the S-1 group (Figure 1A). SL significantly decreased the risk of disease progression by 44% when compared with S-1 (HR, 0.56; 95% CI, 0.37–0.85; P = 0.003). The results for TTP were exactly the same as those for PFS because no death occurred before disease progression. In the pre-specified subgroup analyses of PFS, the effect of SL was better in most categories (supplementary Figure S2A, available at Annals of Oncology online). On multivariate analysis adjusting for patient characteristics such as gender, age, number of metastatic organs, pancreatic resection, and albumin levels in addition to stratification factors (ECOG PS, duration of gemcitabine treatment), SL was significantly associated with improved PFS and OS.

**Table 1. Patient characteristics**

|                        | S-1/LV (n = 69) | S-1 (n = 71) | P-valuea |
|------------------------|-----------------|-------------|----------|
| **n (%)**              |                 |             |          |
| **Gender**             |                 |             |          |
| Male                   | 41 (59.4)       | 38 (53.5)   | F: 0.500 |
| Female                 | 28 (40.6)       | 33 (46.5)   |          |
| **Age (years)**        |                 |             |          |
| Mean                   | 64.2            | 63.3        | t: 0.444 |
| Median                 | 65.0            | 64.0        |          |
| <65                    | 34 (49.3)       | 38 (53.5)   | F: 0.735 |
| ≥65                    | 35 (50.7)       | 33 (46.5)   |          |
| **BSA (m²)**           |                 |             |          |
| Median                 | 1.538           | 1.547       | t: 0.932 |
| Range                  | 1.165–1.861     | 1.225–1.953 |          |
| <1.250                 | 3 (4.3)         | 2 (2.8)     | W: 0.705 |
| 1.250 to <1.500        | 28 (40.6)       | 28 (39.4)   |          |
| 1.500–<                | 38 (55.1)       | 41 (57.7)   |          |
| **ECOG PS**            |                 |             |          |
| 0                      | 45 (65.2)       | 48 (67.6)   | F: 0.858 |
| 1                      | 24 (34.8)       | 23 (32.4)   |          |
| **Albumin (g/dL)**     |                 |             |          |
| <4.0                   | 39 (56.5)       | 30 (42.3)   | F: 0.128 |
| ≥4.0                   | 30 (43.5)       | 41 (57.7)   |          |
| **Sum of the diameter of target lesions (mm)** | 48.0 | 42.1 | t: 0.181 |
| Mean                   | 44.7            | 35.3        |          |
| Median                 |                 |             |          |
| **Pancreatic resection** |               |             |          |
| No                     | 56 (81.2)       | 47 (66.2)   | F: 0.056 |
| Yes                    | 13 (18.8)       | 24 (33.8)   |          |
| **Treatment duration of first-line gemcitabine** | 52 (75.4) | 54 (76.1) | F: 1.000 |
| ≤6 months              | 52 (75.4)       | 54 (76.1)   | F: 1.000 |
| >6 months              | 17 (24.6)       | 17 (23.9)   |          |
| **Previous gemcitabine treatment** | 58 (84.1) | 55 (77.5) | F: 0.394 |
| Advanced               | 58 (84.1)       | 55 (77.5)   | F: 0.394 |
| Recurrent (adjuvant chemotherapy) | 11 (15.9) | 16 (22.5) |          |

ECOG PS, Eastern Cooperative Oncology Group performance status.

aP-values were calculated with Fisher’s exact test (F), t-test (t) or Wilcoxon’s rank-sum test (W).

![Figure 1. Kaplan–Meier curves of (A) progression-free survival (assessed by independent review committee) and (B) overall survival.](https://academic.oup.com/annonc/article-abstract/27/3/502/2196367)
on 27 July 2018
by guest
Downloaded from https://academic.oup.com/annonc/article-abstract/27/3/502/2196367

The RR was 0.82 in favor of SL (95% CI, 0.54–1.22; P = 0.463) (Figure 1B). In the pre-specified subgroup analyses of OS, the effect of SL was better in most categories (supplementary Figure S2B, available at *Annals of Oncology* online). However, some interactions between treatment effect and patient backgrounds, such as prior pancreatic resection and albumin level, were suggested. The HR on multivariate analysis adjusting for patient characteristics was 0.71 in favor of SL (95% CI, 0.47–1.07, P = 0.099) (supplementary Table S1, available at *Annals of Oncology* online).

The RR was 27.5% (95% CI, 17.5%–39.6%) in the SL group and 19.7% (95% CI, 11.2%–30.9%) in the S-1 group (P = 0.322) (supplementary Table S2, available at *Annals of Oncology* online). The DCR was 91.3% (95% CI, 82.0%–96.7%) in the SL group and 71.8% (95% CI, 59.9%–81.9%) in the S-1 group (P = 0.004). The median duration of response was 96.5 days in the SL group and 73.0 days in the S-1 group.

At the cut-off date for PFS analysis, the protocol treatment was being continued in 19 patients (27.5%) in the SL group and 16 patients (22.5%) in the S-1 group. The median TTF was 3.7 months (95% CI, 2.6–3.8 months) in the SL group and 2.4 months (95% CI, 1.8–2.9 months) in the S-1 group. The main reason for treatment discontinuation was disease progression (supplementary Figure S1, available at *Annals of Oncology* online).

Post-protocol treatment was given to 27 patients (39.1%) in the SL group and 30 patients (42.3%) in the S-1 group (supplementary Figure S1, available at *Annals of Oncology* online).

The median duration of response was 96.5 days in the SL group and 73.0 days in the S-1 group.

### safety

The treatment-related grade 3 or 4 adverse events with ≥5 incidences were anemia (9.9% in the SL group versus 11.3% in the S-1 group), lymphopenia (12.7% versus 11.3%), neutropenia (8.5% versus 5.6%), leukopenia (7.0% versus 4.2%), hyponatremia (5.6% versus 2.8%), diarrhea (5.6% versus 4.2%), fatigue (7.0% versus 0.0%), and decreased appetite (14.1% versus 4.2%) (Table 2). Serious adverse events related to the protocol treatment occurred in 11 patients (15.5%) in the SL group and 8 patients (11.3%) in the S-1 group. Two patients in the SL group died from treatment-related sepsis.

The median relative dose intensity (RDI) of S-1 was 91.0% (range, 28.6%–100%) in the SL group and 92.3% (range, 14.3%–103.7%) in the S-1 group. The main reasons for dose reduction of S-1 and treatment interruption were gastrointestinal toxicities in both groups.

### discussion

The significantly better PFS and DCR in the SL group than in the S-1 group suggest that the antitumor activity of S-1 is enhanced by LV in advanced PC. Several clinical studies have shown that adding LV to S-1 enhances antitumor efficacy [12–14]. These results together with the present study provide robust evidence for the enhancement of S-1 activity by LV.
Several regimens of second-line chemotherapy, including OFF and FF plus MM-398, have obtained a median OS of ~6 months [4, 15]. A recent comprehensive analysis of second-line chemotherapy for advanced PC reported that the median OS was 6.0 months in patients who received chemotherapy when compared with only 2.8 months in those who received best supportive care (P = 0.013) [16]. In the GEST study, more than 70% of the patients in the gemcitabine monotherapy group received S-1 monotherapy or S-1-based regimens as second-line chemotherapy [5], and the median OS after gemcitabine failure was ~6.0 months. Development of S-1-based regimens seemed especially attractive in this setting, and we therefore directly estimated the benefits of LV added to S-1 when compared with S-1 monotherapy.

Because PC is not a chemotherapy-sensitive tumor, especially in patients receiving second-line treatment, disease control is considered clinically relevant at present. The main objective of this randomized phase II trial was to estimate the increment in effectiveness obtained by adding LV to S-1, and thereby facilitate planning of a subsequent phase III trial with the primary end point of OS. We designated PFS as the primary end point of our trial, and OS, RR, and DCR were secondary end points. As expected, PFS and DCR were significantly better in the SL group than in the S-1 group.

No difference in OS was observed between the two treatment groups, and several reasons may account for this. First, subsequent treatment might have biased the comparison of OS. The regimens used for subsequent treatment differed substantially between the groups, although the proportions of patients who received subsequent chemotherapy were similar. Secondly, there were non-negligible differences in patient backgrounds such as prior pancreatic resection and the serum albumin level between the treatment groups (Table 1) due to small sample size; and there were some interactions between the patients’ background characteristics and the response to treatment in terms of both PFS and OS (supplementary Figure S2A and B, available at Annals of Oncology online). In particular, both prior pancreatic resection and the serum albumin level were prognostic factors for OS (supplementary Figure S3A and B, available at Annals of Oncology online). In fact, multivariate analysis of OS adjusting not only for stratification factors, but also for patient background characteristics resulted in a lower HR (0.71; 95% CI, 0.47–1.07; P = 0.099) than that of the primary analysis (0.82; 95% CI, 0.54–1.22; P = 0.463). It is speculated that the efficacy of SL, especially in terms of OS, might be underestimated because of some bias related to background characteristics and subsequent treatment. Pancreatic resection and the albumin level should thus be considered as eligibility criteria, stratification factors, or both in future phase III trials.

Treatments were well tolerated, and high RDI (>90%) was maintained in both treatment arms. However, gastrointestinal toxicities were slightly more severe in the SL group. PC is generally associated with malnutrition and sometimes cachexia, especially later in the clinical course of the disease. Cachexia induces sarcopenia, which increases adverse effects of chemotherapy [17]. Serum albumin levels have been reported to be an index of sarcopenia [18]. In fact, the incidences of some adverse effects (e.g. anemia, diarrhea, nausea, and malaise) in our study were higher in patients with low albumin levels than in those with normal albumin levels, especially in the SL group (supplementary Table S3, available at Annals of Oncology online). Patient selection for second-line chemotherapy for advanced PC is considered very important, especially when a toxic regimen is used.

As for second-line treatment after gemcitabine-based chemotherapy, the use of FOLFIRINOX seems to be limited by its severe toxicity. Regimens with relatively mild chemotherapy and a low risk of severe toxicity (e.g. OFF) are most likely suitable for the second-line chemotherapy of PC. In this respect, SL is considered a promising option for second-line treatment after gemcitabine-based regimens in patients with advanced PC.

Our study had several limitations. First, since it was not placebo-controlled, a bias in PFS evaluation cannot be ruled out. To minimize this bias, disease progression in the treatment arms was confirmed by an IRC under blinded conditions. Secondly, the sample size was small, as discussed above. Thirdly, the primary end point was not OS but PFS. Initially, PFS was not expected to be largely affected by patient background characteristics, and post-progression survival was likely to be short in this setting. Therefore, we thought that PFS would be more suitable than OS to evaluate the benefit of adding LV. However, imbalances in the patients’ backgrounds appeared to affect both PFS and OS. Furthermore, differences in subsequent chemotherapy influenced post-progression survival. Although the discrepancy between PFS and OS makes it rather difficult to interpret our results, multivariate analysis of OS suggests a survival benefit of SL.

In conclusion, LV was shown to have an additive effect with S-1 on PFS and DCR and was associated with tolerable toxicity as second-line chemotherapy for patients with gemcitabine-refractory advanced PC. A phase III study to evaluate the survival benefits of SL when compared with S-1 is ongoing in Japan and Korea (JapicCTI-132172).

acknowledgements

We thank the patients, their families, and all the investigators who participated in the study (detailed in the supplementary Appendix SA1, available at Annals of Oncology online) for their contributions. We also thank Yoshihiko Maehara, Keisuke Aiba, Yoshiharu Motoo, Junji Tanaka, Atsushi Sato, Yuku Kobashi, and Yuh Sakata. The authors thank Takanori Tanase (Taiho Pharmaceutical Co., Ltd, Tokyo, Japan) for their contributions to the study design and data analysis. We thank Peter Star of Medical Network K.K., (Tokyo, Japan) for his review of this report, funded by Taiho Pharmaceutical Co., Ltd. We would like to thank Teruaki Matsuyama and Atsuki Shinozaki, Taiho Pharmaceuticals, for overall management of the trial and drafting the manuscript.

funding

This work was funded by Taiho Pharmaceutical Co., Ltd. No grant number applies.

disclosure

MU received honoraria from Abbott, Eli Lilly, Yakult, and AstraZeneca and research funding from Eli Lilly, Kowa, Taiho,
Yakult, Daiichi-Sankyo, Kyowa Hakko Kirin, Zeria, Merck Serono, and AstraZeneca. TO received honoraria from Chugai, Pfizer, Novartis, Taiho, Merck Serono, Eli Lilly, Dainippon Sumitomo, Eisai, and Bayer, and has served as a consultant for Eli Lilly, Yakult, Amgen, Dainippon Sumitomo, Taiho, OncoTherapy Science, Nobelpharma, Ono, Boehringer, NanoCarrier, Chugai, Novartis, and Zeria, and received research funding from Chugai, Eli Lilly, Eisai, Novartis, Shizuka Industry, Takeda Bio Development Center, Yakult, OncoTherapy Science, Otsuka, Taiho, Scoti Medical Labo, Boehringer, Kowa, Kyowa Hakko Kirin, Merck Serono, Ono, Bayer, Pfizer, AstraZeneca, and Dainippon Sumitomo. YO received research funding from Taiho, Chugai, Eli Lilly, Amgen, and Ono. HI is a member of the speakers’ bureau for Junken Medical, MSD, Aska, Astellas, AstraZeneca, Eisai, Otsuka, Olympus, Thermo Fisher Scientific, Century Medical, Daiichi-Sankyo, Dainippon Sumitomo, Taiho, Takeda, Chugai, Eli Lilly, Zeon, Piolax, Hitachi Medical, Fuji Film Medical, Boston Scientific, Yakult, Roche Diagnostics, and Medico’s Hirata, and has received research funding from Junken Medical, Ajinomoto, Eisai, Olympus, Shionogi, Century Medical, Taiho, Chugai, Teijin Pharma, Eli Lilly, Zeon, Hitachi Medical, Pfizer, Fuji Film, Boston Scientific, Merck Serono, Yakult, Piolax, and Public Health Research Center. FA has received honoraria and research funding from Eli Lilly, Yakult, and Taiho. He is also a member of the speakers’ bureau for Taiho. MI has received research funding from Bayer, Novartis, Merck Serono, Kyowa Hakko Kirin, Yakult, Taiho, Eli Lilly, Otsuka, OncoTherapy Science, Boehringer, Kowa, Ono, Eisai, AstraZeneca, Pfizer, Glaxo Smith Kline, and Zeria. He is also a member of the speakers’ bureau for Taiho, Bayer, Novartis, Bristol Myers, Abbott, Takeda, Kyowa Hakko Kirin, Guerbet, Yakult, Eli Lilly, Kowa, Nippon Kayaku, and Daiichi-Sankyo. NM has received honoraria from Taiho, Eli Lilly, Yakult, Novartis, Pfizer, and Kyowa Hakko Kirin and research funding from Taiho, Merck Serono, AstraZeneca, Zeria, and Takeda. He is also a member of the speakers’ bureau for Taiho. KF has received research funding from Taiho. He is also a member of the speakers’ bureau for Taiho, Yakult, Eli Lilly, and Mediphysics, and research funding from Taiho, Eisai, and AstraZeneca. KS has received honoraria from Taiho, and research funding from Taiho, Zeria, and Merck Serono. He has served as a consultant for Taiho. He is also a member of the speakers’ bureau for Taiho. JF has received honoraria from Chugai, Taiho, Eli Lilly, Bayer, Eisai, Novartis, Ono, Yakult, Takeda, Astellas, Daiichi-Sankyo, Dainippon Sumitomo, Bristol Myers, Nippon Kayaku, Ajinomoto, Meiji, Sanoﬁ, Mitsubishi Tanabe, Hisamitsu, Sandoz, Shionogi, Kyowa Hakko Kirin, and Merck Serono and research funding from Ono, Onco Therapy Science, Yakult, Graxo Smith Kline, Taiho, Takeda, Chugai, Eli Lilly, Sanoﬁ, Bayer, Novartis, Merck Serono, Pfizer, Daiichi-Sankyo, Torii, Nippon Kayaku, and Bristol Myers. He has served as a consultant for Kyowa Hakko Kirin, Zeria, AstraZeneca, Merck Serono, Graxo Smith Kline, Chugai, Taiho, Bayer, Eisai, Yakult, Fujifilm, Boehringer Ingelheim, Kowa, Astellas, Onco Therapy Science, Otsuka, Janssen, Nobopharma, and J-Pharma. KS has received research funding from Taiho, Yakult, Bristol Myers, and Chugai and honoraria from Takeda, Taiho, Yakult, Chugai, Eli Lilly, Bristol Myers, Eisai, Sawai, Hisamitsu, Meiji, and Ono. TI has received honoraria, research funding, and travel and accommodation fees from Taiho. He has served as a consultant for Taiho. He is also a member of the speakers’ bureau for Taiho. SN has received honoraria and research funding from Taiho. He is also a member of the speakers’ bureau for Taiho. HB has received honoraria from Taiho, and research funding from Taiho, Yakult, Takeda, and Chugai. He has served as a consultant for Taiho. He is also a member of the speakers’ bureau for Taiho, Ono, Takeda, and Chugai. YK has received honoraria and research funding from Taiho. He has served as a consultant for Taiho. He is also a member of the speakers’ bureau for Taiho. MT has served as a consultant for AstraZeneca, Hisamitsu, AbbVie, Kyorin, Sanoﬁ, Takeda, and Mitsubishi Tanabe. IH has received research funding from Taiho, and honoraria from Taiho, Chugai, Yakult, Daiichi-Sankyo, and Bristol Myers. He has served as a consultant for Taiho, Chugai, Yakult, and Daiichi-Sankyo. NB has received research funding from Taiho and Chugai, and honoraria from Taiho, Chugai, Yakult, and Daiichi-Sankyo. He has served as a consultant for Taiho. He is also a member of the speakers’ bureau for Taiho.

references

1. Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69–90.
2. Conroy T, Desseigne F, Ychou M et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817–1825.
3. Von Hoff DD, Ervin T, Arena FP et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369: 1691–1703.
4. Oettel H, Riess H, Stüeler JM et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONNO-003 trial. J Clin Oncol 2014; 32: 2423–2429.
5. Uno H, Ioka T, Ikeda M et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol 2013; 31: 1640–1648.
6. Morizane C, Okusaka T, Furuse J et al. A Phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol 2009; 63: 313–319.
7. Ohkawa S, Okusaka T, Isayama H et al. Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer. Br J Cancer 2015; 112: 1428–1434.
8. Mizuno N, Yamao K, Komatsu Y et al. Randomized phase II trial of S-1 versus S-1 plus irinotecan (IRIS) in patients with gemcitabine-refractory pancreatic cancer. J Clin Oncol 2013; 31 (Suppl. 4); abstr 263.
9. Thirion P, Michiels S, Pignon JP et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 2004; 22: 3766–3775.
10. Tsukido S, Uchida J, Tsujimoto H et al. Oral fluoropyrimidine S-1 combined with leucovorin is a promising therapy for colorectal cancer: evidence from a xenograft model of bolite-depleted mice. Mol Med Rep 2009; 2: 393–398.
11. Van Cutsem E, Findlay M, Osterwalder B et al. Caprectiban, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol 2000; 18: 1337–1345.
12. Kozumi W, Boku N, Yamaguchi K et al. Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer. Ann Oncol 2010; 21: 766–771.
13. Denda T, Li J, Xu R et al. Phase II study of S-1 plus leucovorin (a new 1-week treatment regimen followed by a 1-week rest period) in patients with untreated metastatic colorectal cancer in Japan and China. J Clin Oncol 2012; 30 (Suppl. 4); abstr 598.
Epstein–Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin

S. J. Kim1,2*, J. H. Kim3, C. S. Ki4, Y. H. Ko5, J. S. Kim6 & W. S. Kim7

1Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul; 2Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul; 3Samsung Biomedical Research Institute, Samsung Medical Center, Seoul; Departments of 4Laboratory Medicine and Genetics; 5Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul; 6Department of Internal Medicine, Yonsei University College of Medicine, Seoul; 7Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Received 9 August 2015; revised 30 September 2015; accepted 21 November 2015

Background: Romidepsin, a histone deacetylase (HDAC) inhibitor, has been approved for the treatment of relapsed and refractory peripheral T-cell lymphoma. However, the efficacy and safety of romidepsin has never been studied in patients with relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma (ENKTL).

Patients and methods: We conducted an open-label, prospective pilot study to evaluate the efficacy and feasibility of romidepsin in the treatment of patients with ENKTL. The treatment was intravenous infusion of romidepsin (14 mg/m²) for 4 h on days 1, 8, and 15 of a 28-day cycle, and was repeated until disease progression or the occurrence of unacceptable toxicity.

Results: A total of five patients enrolled on to this pilot study. However, three patients developed fever and elevated liver enzyme and bilirubin levels immediately after their first administration of romidepsin. We suspected that these events were associated with Epstein–Barr virus (EBV) reactivation because of the rapidly elevated EBV DNA titers in blood from these patients. An in vitro study with the ENKTL cell line SNK-6 cells also showed that HDAC inhibitors including romidepsin increased the copy number of EBV DNA in a dose-dependent manner. These findings suggested that romidepsin-induced histone acetylation reversed the repressed state of the genes required for EBV reactivation and that romidepsin treatment may have caused EBV reactivation in EBV-infected tumor cells in ENKTL patients. Therefore, we discontinued the enrollment of patients into this pilot study.

Conclusions: Our study suggests that the use of romidepsin may cause severe EBV reactivation in patients with ENKTL.

Key words: extranodal NK/T-cell lymphoma, romidepsin, EBV reactivation

*Correspondence to: Prof. Won Seog Kim, Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 135-710, Korea. Tel: +82-2-3410-6548; Fax: +82-2-3410-1754; E-mail: wskimsmc@sksu.edu

© The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.